Max Robotics — Global Service Robot Directory + US Certification

About

Yoshihiro Matsuno is a clinician-researcher whose work bridges surgical oncology, urological pathology, and the molecular underpinnings of prostate cancer progression. His most cited study investigates biglycan, a stromal proteoglycan, as a prognostic biomarker in prostate cancer, demonstrating that its expression correlates with progression to castration-resistant prostate cancer (CRPC). This work, with 8 citations, offers a potential new avenue for risk stratification in patients facing treatment resistance. In a separate case series, Matsuno explores the role of robotic thymectomy in Good’s syndrome—a rare immunodeficiency linked to thymoma—highlighting how minimally invasive surgery can improve outcomes in this vulnerable population. Though his citation counts are early-stage, his contributions are notable for addressing clinically underexplored intersections: stromal biology in CRPC and surgical management of paraneoplastic immunodeficiency. Matsuno’s research reflects a dual commitment to advancing precision prognostics and refining surgical techniques for rare, high-risk conditions. His work is particularly relevant for students and researchers interested in tumor microenvironment biomarkers, urological oncology, and the surgical treatment of thymoma-associated autoimmune disorders.